51![iCo Therapeutics July 1, 2014 Andrew Rae, President & CEO[removed]www.icotherapeutics.com / TSX-V: ICO iCo Therapeutics July 1, 2014 Andrew Rae, President & CEO[removed]www.icotherapeutics.com / TSX-V: ICO](https://www.pdfsearch.io/img/60d007ff172118647ba7472cd1968552.jpg) | Add to Reading ListSource URL: www.icotherapeutics.comLanguage: English - Date: 2014-07-23 09:04:29
|
---|
52![COMMUNIQUÉ DE PRESSE Sanofi et Regeneron annoncent les résultats positifs d’une étude de Phase 2b du dupilumab dans le traitement de la dermatite atopique modérée à sévère – Publication aujourd’hui des ré COMMUNIQUÉ DE PRESSE Sanofi et Regeneron annoncent les résultats positifs d’une étude de Phase 2b du dupilumab dans le traitement de la dermatite atopique modérée à sévère – Publication aujourd’hui des ré](https://www.pdfsearch.io/img/e29d14d3c244681cf01c98f4ffe4c7f8.jpg) | Add to Reading ListSource URL: www.sanofi.comLanguage: French - Date: 2014-07-09 16:57:14
|
---|
53![PRESS RELEASE Sanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis - Results from Earlier Clinical Trials Published Today in the New Engla PRESS RELEASE Sanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis - Results from Earlier Clinical Trials Published Today in the New Engla](https://www.pdfsearch.io/img/044d8ba43ec94986ed9c13a33b9e7c48.jpg) | Add to Reading ListSource URL: en.sanofi.comLanguage: English - Date: 2014-07-09 16:57:27
|
---|
54![Regeneron Pharmaceuticals 483 Inspection Regeneron Pharmaceuticals 483 Inspection](https://www.pdfsearch.io/img/1f85d56999a5ed23d4f1b70ce6ed2d24.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
55![New York Medical College, Hawthorne The Bristal at White Plains Regeneron, Tarrytown New York Medical College, Hawthorne The Bristal at White Plains Regeneron, Tarrytown](https://www.pdfsearch.io/img/8eaa9763e04242e7d0869980b250f431.jpg) | Add to Reading ListSource URL: westchesterny.orgLanguage: English - Date: 2014-03-03 10:47:48
|
---|
56![Rilonacept Regeneron, INN-rilonacept Rilonacept Regeneron, INN-rilonacept](https://www.pdfsearch.io/img/4bb48568f565f43a056a36dda8f5d372.jpg) | Add to Reading ListSource URL: www.regeneron.comLanguage: English - Date: 2012-02-08 13:32:03
|
---|
57![HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA.](https://www.pdfsearch.io/img/e6bc242a9842c56d99804b5842e03726.jpg) | Add to Reading ListSource URL: www.regeneron.comLanguage: English - Date: 2014-02-14 16:41:40
|
---|
58![ZALTRAP® (ziv-aflibercept) ZALTRAP® (ziv-aflibercept)](https://www.pdfsearch.io/img/4392dd071be89b0736cef4dfeff43cf4.jpg) | Add to Reading ListSource URL: www.regeneron.comLanguage: English - Date: 2013-11-08 09:50:49
|
---|
59![PRESS RELEASE Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR - Both doses of investigational drug sarilumab met all three co-primary endpoints - New PRESS RELEASE Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR - Both doses of investigational drug sarilumab met all three co-primary endpoints - New](https://www.pdfsearch.io/img/f4da1bd47f042e5dc4a1900d0e4489b1.jpg) | Add to Reading ListSource URL: en.sanofi.comLanguage: English - Date: 2014-06-12 01:00:21
|
---|
60![A Breakthrough Year 2012 Annual Report A Breakthrough Year 2012 Annual Report](https://www.pdfsearch.io/img/1854de7bc0f0b2a475c8c79b0f62c3c3.jpg) | Add to Reading ListSource URL: files.shareholder.comLanguage: English |
---|